Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Novel Anti-PTEN Rabbit Monoclonal Antibody Optimized for Immunohistochemistry Testing

By BiotechDaily International staff writers
Posted on 16 Sep 2013
Image: SP218 staining PTEN loss on colon adenocarcinoma sample (Photo courtesy of Spring Bioscience, Inc.).
Image: SP218 staining PTEN loss on colon adenocarcinoma sample (Photo courtesy of Spring Bioscience, Inc.).
Cancer researchers now have available a rabbit monoclonal antibody for the protein produced by the PTEN tumor suppressor gene that has been optimized for immunohistochemistry (IHC) testing.

PTEN is one of the most commonly lost tumor suppressors in human cancer. During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, prostate cancer, and reduced expression is found in many other tumor types such as lung and breast cancer. When the PTEN enzyme is functioning properly, it acts as part of a chemical pathway that signals cells to stop dividing and causes cells to undergo programmed cell death (apoptosis) when necessary. These functions prevent uncontrolled cell growth that can lead to the formation of tumors. There is also evidence that the protein made by the PTEN gene may play a role in both cell movement and adhesion of cells to surrounding tissues.

A new tool for the study the PTEN enzyme was developed by Spring Bioscience (Pleasanton, CA, USA). Spring has recently added the SP218 anti-PTEN rabbit monoclonal antibody to its portfolio of antibodies for cancer research.

The SP218 anti-PTEN monoclonal antibody for IHC on FFPE (formalin-fixed, paraffin-embedded) tissue is available in 0.1, 0.5, and 1.0 mL concentrate configurations, as well as in a 7.0-mL ready-to-use format. Recommended staining protocols are available for manual, semi-automated, and fully automated platforms. SP218 is for research use only and not for use in diagnostic procedures.

"SP218's robust and consistent performance with IHC analysis is particularly important given PTEN's potential as a companion diagnostic biomarker," said Michael Rivers, general manager of Spring Bioscience. "With SP218, we are seeking to set a new gold standard across the industry by offering an extremely sensitive, highly specific antibody optimized for IHC testing that will allow researchers and pathologists to interpret PTEN status with utmost confidence. For our customers, this means we are continuing to offer unparalleled value through superior tests that lead the market in innovation, reliability, and quality."

Related Links:
Spring Bioscience



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: To adhere to catheters and start urinary tract infections, bacteria extend microscopic fibers with sticky proteins at their ends. Researchers have developed a vaccine that blocks the EbpA protein, visible as a white bulge above, and stops infections in mice (Photo courtesy of Dr. John Heuser, Washington University School of Medicine).

Blocking Binding of Bacteria to Fibrinogen Prevents Biofilm Formation and Catheter-Associated Bladder Infection in Mice

A team of molecular microbiologists has identified and targeted a critical step in biofilm formation and developed a vaccine that prevents catheter-associated urinary tract infections in mice.... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.